ZURICH, Nov 23 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) on Tuesday said it had obtained a global license from U.S. biotech group Genzyme (GENZ.O) to develop a test for lung cancer cell mutations. Basel-based Roche said the goal was to detect epidermal growth-factor receptor (EGFR) mutations, in order to improve administration of its drug Tarceva, a pill taken once a day for treating lung and pancreatic cancer.
